Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BetterLife Pharma ( (TSE:BETR) ) has shared an announcement.
BetterLife Pharma has provided a scientific update on BETR-001, a promising compound for treating psychiatric disorders like depression and anxiety. BETR-001 activates the 5HT2A receptor without hallucinogenic effects, unlike other psychedelics, offering a novel treatment paradigm. It avoids cardiac safety issues by not activating the 5HT2B receptor and does not induce tolerance, allowing for daily use. With a composition of matter patent granted, BetterLife plans to start human trials in 2026, potentially impacting the treatment landscape for psychiatric disorders.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.
BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Their primary products include BETR-001, a non-hallucinogenic neuroplastogen, and BETR-002, based on honokiol, for treating various psychiatric and neurological disorders.
Average Trading Volume: 54,828
Technical Sentiment Signal: Sell
Current Market Cap: C$11.01M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.